The SCRUM-Japan MONSTAR-SCREEN (SCRUM-MONSTAR) project, initiated in 2015, began with genomic testing and evolved to incorporate more comprehensive approaches. Recently, it has expanded to include spatial transcriptomics and other omics analyses—positioning itself at the forefront of integrating advanced molecular profiling techniques into clinical cancer research. This nationwide molecular profiling initiative employs AI-driven multiomics analyses to facilitate precision medicine and optimize drug development. This has contributed to numerous therapeutic and diagnostic advancements in oncology, including the development of novel biomarkers and targeted therapies.

Dr. Imai, from the National Cancer Center Hospital East, and Dr. Park, from GxD Inc., will present their latest findings and future directions from the SCRUM-MONSTAR project. By elucidating the spatial context of gene expression in tumors, this study has the potential to herald a new era in precision oncology. The significance of this study lies in its ability to delve deeper into cancer mechanisms, offering new paradigms for cancer classification, drug discovery, and treatment optimization that extend beyond individual patient care. Through this work, we aim to demonstrate how comprehensive omics analysis, including spatial transcriptomics, can accelerate our understanding of cancer biology and drive advancements in personalized cancer treatment.

• Learn how spatial transcriptomics can accelerate understanding of cancer biology and drive advancements in personalized cancer treatment.

• Hear how 10x Genomics, a leader in spatial, has made this project possible with the Xenium Analyzer.

• Understand how accelerated computing and artificial intelligence play a pivotal role in scalability and unlock future research possibilities.

Content

content goes here